EP3526334A4 - Tgfbetar2-homing-endonukleasevarianten, zusammensetzungen und verfahren zur verwendung - Google Patents
Tgfbetar2-homing-endonukleasevarianten, zusammensetzungen und verfahren zur verwendung Download PDFInfo
- Publication number
- EP3526334A4 EP3526334A4 EP17861537.3A EP17861537A EP3526334A4 EP 3526334 A4 EP3526334 A4 EP 3526334A4 EP 17861537 A EP17861537 A EP 17861537A EP 3526334 A4 EP3526334 A4 EP 3526334A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- tgfbetar2
- compositions
- methods
- endonuclease variants
- endonuclease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004533 Endonucleases Human genes 0.000 title 1
- 108010042407 Endonucleases Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46443—Growth factors
- A61K39/464434—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464469—Tumor associated carbohydrates
- A61K39/464471—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662409163P | 2016-10-17 | 2016-10-17 | |
US201662414260P | 2016-10-28 | 2016-10-28 | |
PCT/US2017/057014 WO2018075541A1 (en) | 2016-10-17 | 2017-10-17 | TGFβR2 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3526334A1 EP3526334A1 (de) | 2019-08-21 |
EP3526334A4 true EP3526334A4 (de) | 2020-09-30 |
Family
ID=62018976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP17861537.3A Pending EP3526334A4 (de) | 2016-10-17 | 2017-10-17 | Tgfbetar2-homing-endonukleasevarianten, zusammensetzungen und verfahren zur verwendung |
Country Status (8)
Country | Link |
---|---|
US (1) | US11530395B2 (de) |
EP (1) | EP3526334A4 (de) |
JP (2) | JP7060591B2 (de) |
CN (1) | CN110050066A (de) |
AU (1) | AU2017346683B2 (de) |
CA (1) | CA3040157A1 (de) |
MA (1) | MA46543A (de) |
WO (1) | WO2018075541A1 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
SG11201901757YA (en) | 2016-09-08 | 2019-03-28 | Bluebird Bio Inc | Pd-1 homing endonuclease variants, compositions, and methods of use |
US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
CN110904045A (zh) * | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
AU2019395334A1 (en) * | 2018-12-10 | 2021-06-24 | 2Seventy Bio, Inc. | PDCD-1 homing endonuclease variants |
WO2020123371A2 (en) * | 2018-12-10 | 2020-06-18 | Bluebird Bio, Inc. | Homing endonuclease variants |
WO2020223535A1 (en) * | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
WO2023081900A1 (en) * | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014172584A1 (en) * | 2013-04-17 | 2014-10-23 | Baylor College Of Medicine | IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER |
WO2014191527A1 (en) * | 2013-05-31 | 2014-12-04 | Cellectis | A laglidadg homing endonuclease cleaving the t cell receptor alpha gene and uses thereof |
WO2014191525A1 (en) * | 2013-05-31 | 2014-12-04 | Cellectis | A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
GB8918616D0 (en) | 1989-08-15 | 1989-09-27 | Univ Glasgow | Herpes simplex virus type 1 mutant |
US5804413A (en) | 1992-07-31 | 1998-09-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains for gene transfer |
GB9415319D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | HSV viral vector |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
EP1002119A1 (de) | 1997-07-31 | 2000-05-24 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Zielgerichtete hsv-vektoren |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
FR2777909B1 (fr) | 1998-04-24 | 2002-08-02 | Pasteur Institut | Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex |
US6692736B2 (en) | 2000-03-24 | 2004-02-17 | Cell Genesys, Inc. | Cell-specific adenovirus vectors comprising an internal ribosome entry site |
AU2001269723B9 (en) | 2000-06-01 | 2006-11-16 | University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
EP1828390B1 (de) | 2004-12-15 | 2012-06-13 | The University Of North Carolina At Chapel Hill | Chimäre vektoren |
AU2007347328B2 (en) * | 2007-02-19 | 2013-03-07 | Cellectis | LAGLIDADG homing endonuclease variants having novel substrate specificity and use thereof |
ES2575412T3 (es) | 2007-10-31 | 2016-06-28 | Precision Biosciences, Inc. | Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas |
US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
EP2396343B1 (de) | 2009-02-11 | 2017-05-17 | The University of North Carolina At Chapel Hill | Modifizierte virusvektoren sowie verfahren zu ihrer herstellung und verwendung |
US20110294217A1 (en) * | 2009-02-12 | 2011-12-01 | Fred Hutchinson Cancer Research Center | Dna nicking enzyme from a homing endonuclease that stimulates site-specific gene conversion |
WO2011088081A1 (en) | 2010-01-12 | 2011-07-21 | The University Of North Carolina At Chapel Hill | Restrictive inverted terminal repeats for viral vectors |
WO2011097456A2 (en) | 2010-02-05 | 2011-08-11 | The University Of North Carolina At Chapel Hill | Compositions and methods for enhanced parvovirus transduction |
US20140148361A1 (en) * | 2010-06-07 | 2014-05-29 | Barry L. Stoddard | Generation and Expression of Engineered I-ONUI Endonuclease and Its Homologues and Uses Thereof |
ES2906059T3 (es) | 2011-02-28 | 2022-04-13 | Seattle Childrens Res Institute | Endonucleasas de acoplamiento con enzimas de procesamiento de extremos que impulsan la interrupción génica de alta eficiencia |
US8450107B1 (en) | 2011-11-30 | 2013-05-28 | The Broad Institute Inc. | Nucleotide-specific recognition sequences for designer TAL effectors |
ES2883131T3 (es) * | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
EP3027204B1 (de) | 2013-07-29 | 2022-01-05 | 2seventy bio, Inc. | Multilaterale signalisierungsproteine und verwendungen davon |
JP2019525759A (ja) | 2016-07-25 | 2019-09-12 | ブルーバード バイオ, インコーポレイテッド | Bcl11aホーミングエンドヌクレアーゼバリアント、組成物、および使用方法 |
EP3500696A4 (de) | 2016-08-16 | 2020-04-08 | Bluebird Bio, Inc. | Il-10-rezeptor-alpha-homing-endonuklease-varianten, zusammensetzungen und verfahren zur verwendung |
EP3504335A4 (de) | 2016-08-23 | 2020-04-15 | Bluebird Bio, Inc. | Tim3-homing-endonuklease-varianten, zusammensetzungen und verfahren zur verwendung |
SG11201901757YA (en) | 2016-09-08 | 2019-03-28 | Bluebird Bio Inc | Pd-1 homing endonuclease variants, compositions, and methods of use |
MX2019004156A (es) | 2016-10-11 | 2019-09-26 | Bluebird Bio Inc | Variantes de endonucleasa homing de receptor de linfocitos t alfa (tcralpha). |
-
2017
- 2017-10-17 EP EP17861537.3A patent/EP3526334A4/de active Pending
- 2017-10-17 CN CN201780076229.5A patent/CN110050066A/zh active Pending
- 2017-10-17 US US16/341,228 patent/US11530395B2/en active Active
- 2017-10-17 MA MA046543A patent/MA46543A/fr unknown
- 2017-10-17 WO PCT/US2017/057014 patent/WO2018075541A1/en unknown
- 2017-10-17 AU AU2017346683A patent/AU2017346683B2/en active Active
- 2017-10-17 CA CA3040157A patent/CA3040157A1/en active Pending
- 2017-10-17 JP JP2019520527A patent/JP7060591B2/ja active Active
-
2022
- 2022-04-14 JP JP2022066868A patent/JP2022103174A/ja not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014172584A1 (en) * | 2013-04-17 | 2014-10-23 | Baylor College Of Medicine | IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER |
WO2014191527A1 (en) * | 2013-05-31 | 2014-12-04 | Cellectis | A laglidadg homing endonuclease cleaving the t cell receptor alpha gene and uses thereof |
WO2014191525A1 (en) * | 2013-05-31 | 2014-12-04 | Cellectis | A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof |
Non-Patent Citations (5)
Title |
---|
C. M. BOLLARD ET AL: "Adapting a transforming growth factor beta -related tumor protection strategy to enhance antitumor immunity", BLOOD, vol. 99, no. 9, 1 May 2002 (2002-05-01), pages 3179 - 3187, XP055080715, ISSN: 0006-4971, DOI: 10.1182/blood.V99.9.3179 * |
FOSTER AARON E ET AL: "Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 31, no. 5, 1 June 2008 (2008-06-01), pages 500 - 505, XP009138881, ISSN: 1524-9557 * |
L ZHANG ET AL: "Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy", GENE THERAPY, vol. 20, no. 5, 13 September 2012 (2012-09-13), pages 575 - 580, XP055131633, ISSN: 0969-7128, DOI: 10.1038/gt.2012.75 * |
TAKEUCHI R ET AL: "Redesign of extensive protein-DNA interfaces of meganucleases using iterative cycles of in vitro compartmentalization", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 111, no. 11, 1 March 2014 (2014-03-01), pages 4061 - 4066, XP002757991, ISSN: 0027-8424, [retrieved on 20140303], DOI: 10.1073/PNAS.1321030111 * |
YANG L ET AL: "TGF-@b and immune cells: an important regulatory axis in the tumor microenvironment and progression", TRENDS IN IMMUNOLOGY, ELSEVIER LTD. * TRENDS JOURNALS, GB, vol. 31, no. 6, 1 June 2010 (2010-06-01), pages 220 - 227, XP027079217, ISSN: 1471-4906, [retrieved on 20100601], DOI: 10.1016/J.IT.2010.04.002 * |
Also Published As
Publication number | Publication date |
---|---|
JP7060591B2 (ja) | 2022-04-26 |
JP2019535240A (ja) | 2019-12-12 |
EP3526334A1 (de) | 2019-08-21 |
AU2017346683B2 (en) | 2024-04-18 |
CN110050066A (zh) | 2019-07-23 |
AU2017346683A1 (en) | 2019-05-09 |
MA46543A (fr) | 2019-08-21 |
CA3040157A1 (en) | 2018-04-26 |
US20200123515A1 (en) | 2020-04-23 |
WO2018075541A1 (en) | 2018-04-26 |
JP2022103174A (ja) | 2022-07-07 |
US11530395B2 (en) | 2022-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL265045B1 (en) | Variants of endonuclease pd-1, compositions and methods of use | |
EP3704239A4 (de) | Casz-zusammensetzungen und verfahren zur verwendung | |
EP3523437A4 (de) | Oligonukleotidzusammensetzungen und verfahren dafür | |
EP3452596A4 (de) | Oligonukleotidzusammensetzungen und verfahren dafür | |
EP3487994A4 (de) | Bcl11a-homing-endonukleasevarianten, zusammensetzungen und verfahren zur verwendung | |
EP3313404A4 (de) | Therapeutische zusammensetzungen, kombinationen und verfahren zur verwendung | |
EP3352774A4 (de) | Flavonoidzusammensetzungen und verfahren zur verwendung | |
EP3500696A4 (de) | Il-10-rezeptor-alpha-homing-endonuklease-varianten, zusammensetzungen und verfahren zur verwendung | |
EP3478308A4 (de) | Cannabiszusammensetzungen und -verfahren | |
EP3325017A4 (de) | Oligonukleotidzusammensetzungen und verfahren dafür | |
EP3337823A4 (de) | Trägerbindemittelzusammensetzungen sowie verfahren zur herstellung und verwendung davon | |
EP3630962A4 (de) | Cblb-endonuklease-varianten, zusammensetzungen und verfahren zur verwendung | |
EP3268018A4 (de) | Bakterielle zusammensetzungen und verfahren zur verwendung davon | |
EP3704254A4 (de) | Cas12c-zusammensetzungen und verfahren zur verwendung | |
EP3435956A4 (de) | Fotostabilisierte zusammensetzungen und verfahren zur verwendung davon | |
EP3526334A4 (de) | Tgfbetar2-homing-endonukleasevarianten, zusammensetzungen und verfahren zur verwendung | |
EP3557998A4 (de) | Verbindungen, zusammensetzungen und verfahren zur verwendung | |
EP3294289A4 (de) | Verwendung von cannabis zur behandlung von fibromyalgie, verfahren und zusammensetzungen davon | |
EP3408344A4 (de) | Verfahren und zusammensetzungen zur bohrlochbehandlung | |
EP3386927A4 (de) | Polymerzusammensetzungen und verfahren zur verwendung | |
EP3503879A4 (de) | Zusammensetzung und verfahren dafür | |
EP3504335A4 (de) | Tim3-homing-endonuklease-varianten, zusammensetzungen und verfahren zur verwendung | |
EP3166892A4 (de) | Kesselsteinhemmungszusammensetzungen sowie verfahren zur herstellung und verwendung davon | |
EP3349743A4 (de) | Verfahren und zusammensetzungen zur hemmung der dcn1-ubc12-interaktion | |
EP3436083A4 (de) | Neuartige zusammensetzungen und verfahren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190515 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200828 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/87 20060101AFI20200824BHEP Ipc: C12N 15/63 20060101ALI20200824BHEP |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: 2SEVENTY BIO, INC. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240131 |